FIFTH THIRD BANCORP - BIO-TECHNE CORP ownership

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 549 filers reported holding BIO-TECHNE CORP in Q1 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.

About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Quarter-by-quarter ownership
FIFTH THIRD BANCORP ownership history of BIO-TECHNE CORP
ValueSharesWeighting
Q3 2023$240,559
-29.7%
3,534
-15.7%
0.00%
-50.0%
Q2 2023$342,030
+54.3%
4,190
+40.2%
0.00%
+100.0%
Q1 2023$221,680
+15.0%
2,988
+28.5%
0.00%0.0%
Q4 2022$192,696
+96.6%
2,325
+575.9%
0.00%0.0%
Q3 2022$98,000
-49.0%
344
-38.0%
0.00%0.0%
Q2 2022$192,000
+16.4%
555
+45.3%
0.00%0.0%
Q1 2022$165,000
+58.7%
382
+90.0%
0.00%
Q4 2021$104,000
+42.5%
201
+33.1%
0.00%
Q3 2021$73,000
+114.7%
151
+101.3%
0.00%
Q2 2021$34,000
+47.8%
75
+23.0%
0.00%
Q1 2021$23,000
-88.6%
61
-90.4%
0.00%
-100.0%
Q4 2020$201,000
+53.4%
634
+20.1%
0.00%0.0%
Q3 2020$131,000
-10.3%
528
-4.3%
0.00%0.0%
Q2 2020$146,000
+8.1%
552
-22.6%
0.00%0.0%
Q1 2020$135,000
-21.1%
713
-8.7%
0.00%0.0%
Q4 2019$171,000
+37.9%
781
+23.2%
0.00%0.0%
Q3 2019$124,000
-8.8%
634
-2.5%
0.00%0.0%
Q2 2019$136,000
-14.5%
650
-18.8%
0.00%0.0%
Q1 2019$159,000
+42.0%
800
+3.6%
0.00%0.0%
Q4 2018$112,000
-29.1%
7720.0%0.00%0.0%
Q3 2018$158,000
+33.9%
772
-3.4%
0.00%0.0%
Q2 2018$118,000
-3.3%
799
-1.5%
0.00%0.0%
Q1 2018$122,000
+48.8%
811
+28.7%
0.00%0.0%
Q4 2017$82,000
+28.1%
630
+19.8%
0.00%
Q3 2017$64,000
-1.5%
526
-5.6%
0.00%
Q2 2017$65,000
+22.6%
557
+5.9%
0.00%
Q1 2017$53,000
-1.9%
5260.0%0.00%
Q4 2016$54,000
-14.3%
526
-8.2%
0.00%
-100.0%
Q3 2016$63,000
-4.5%
573
-2.7%
0.00%0.0%
Q2 2016$66,000
+17.9%
589
-0.7%
0.00%
Q1 2016$56,000
-6.7%
593
-10.4%
0.00%
-100.0%
Q4 2015$60,000
-22.1%
662
-20.6%
0.00%0.0%
Q3 2015$77,000
-6.1%
834
-0.2%
0.00%0.0%
Q2 2015$82,000
-18.8%
836
-16.7%
0.00%0.0%
Q1 2015$101,000
+13.5%
1,003
+4.6%
0.00%0.0%
Q4 2014$89,0009590.00%
Other shareholders
BIO-TECHNE CORP shareholders Q1 2022
NameSharesValueWeighting ↓
Broadcrest Asset Management, LLC 300,000$24,489,00021.05%
Montanaro Asset Management Ltd 388,800$31,737,7445.02%
Sandhill Capital Partners LLC 502,447$41,014,7753.74%
Brown Capital Management 3,160,892$258,023,6143.66%
DF DENT & CO INC 3,275,617$267,388,6403.62%
Ownership Capital B.V. 2,282,104$186,288,1503.26%
Jackson Square Partners, LLC 1,361,789$111,162,8363.24%
STONE RUN CAPITAL, LLC 88,135$7,194,4603.20%
Pembroke Management, LTD 339,591$27,720,8132.99%
Summit Creek Advisors LLC 283,693$23,157,8602.90%
View complete list of BIO-TECHNE CORP shareholders